This article is more than 5 years old. Information may no longer be current.
Nicox enters agreement to help promote Sjögren’s syndrome test
Click Here to Manage Email Alerts
Nicox has entered into an exclusive agreement with Immco Diagnostics to help promote Immco’s proprietary laboratory test for early detection and diagnosis of Sjögren’s syndrome, according to a press release.
The test, developed at the University of Buffalo and Immco Diagnostics, uses three novel biomarkers (SP-1, CA-6 and PSP) along with traditional markers (ANA, Ro, La and RF) for early detection with high sensitivity.
“Rheumatologists have been challenged with the management of late-stage Sjögren’s patients for years with mixed results,” Julian L. Ambrus Jr., MD, from the University of Buffalo, said in a press release. “The problem has always been that there was no effective method to easily diagnose these patients earlier in the disease process.”
Nicox will market the test to eye care practitioners in the United States, Canada, Puerto Rico and Mexico and receive a majority share of revenue that comes from practitioners. Immco will administer the test in Buffalo, N.Y., and manage regulatory activities and reimbursement.
The test was approved in the U.S. this year. It is expected to launch commercially by Nicox in the second half of the year.